id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2025-E-1227-0006,FDA,FDA-2025-E-1227,Determination of Regulatory Review Period for Purposes of Patent Extension; ALFAPUMP,Notice,Determinations,2026-02-06T05:00:00Z,2026,2,2026-02-06T05:00:00Z,2026-04-08T03:59:59Z,2026-02-11T02:11:43Z,2026-02384,1,0,09000064b9195d0d
FDA-2025-E-1227-0005,FDA,FDA-2025-E-1227,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2025-11-21T05:00:00Z,2025,11,2025-11-21T05:00:00Z,,2025-11-22T02:32:42Z,,0,0,09000064b908d952
FDA-2025-E-1227-0004,FDA,FDA-2025-E-1227,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2025-09-22T04:00:00Z,2025,9,2025-09-22T04:00:00Z,,2025-09-22T23:24:18Z,,0,0,09000064b8fd20ea
FDA-2025-E-1227-0003,FDA,FDA-2025-E-1227,Letter from FDA CDER to U. S. Patent and Trademark Office,Other,Letter(s),2025-06-16T04:00:00Z,2025,6,2025-06-16T04:00:00Z,,2025-06-16T19:24:58Z,,0,0,09000064b8e0ecb7
FDA-2025-E-1227-0002,FDA,FDA-2025-E-1227,"Patent Extension Application from Greenberg Traurig, LLP (on behalf of Sequana Medical NV)",Other,Application,2025-05-14T04:00:00Z,2025,5,2025-05-14T04:00:00Z,,2025-05-21T22:12:27Z,,0,0,09000064b8d48f39
FDA-2025-E-1227-0001,FDA,FDA-2025-E-1227,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2025-05-14T04:00:00Z,2025,5,2025-05-14T04:00:00Z,,2025-05-21T22:12:27Z,,0,0,09000064b8d48f38